Publish in this journal
Journal Information
Vol. 67. Issue 7.
Pages 538-544 (July 2014)
Not available
Vol. 67. Issue 7.
Pages 538-544 (July 2014)
Original article
Full text access
Demographic and Clinical Characteristics of Patients With Stable Coronary Artery Disease: Results From the CLARIFY Registry in Spain
Características demográficas y clínicas de los pacientes con enfermedad coronaria estable: resultados del registro CLARIFY en España
José L. Zamoranoa,
Corresponding author

Corresponding author: Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Ctra. de Colmenar Km 9,100, 28034 Madrid, Spain.
, Xavier García-Mollb, Roberto Ferraric, Nicola Greenlawd
a Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Madrid, Spain
b Servicio de Cardiología, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
c Servicio de Cardiología, Hospital Universitario de Ferrara, Ferrara, Italy
d Robertson Centre for Biostatistics, University of Glasgow, Glasgow, United Kingdom
This item has received
Article information
Full Text
Download PDF
Tables (6)
Table 1. Sociodemographic Characteristics
Table 2. Risk Factors and Lifestyle Habits
Table 3. Medical History
Table 4. Baseline Clinical Profile
Table 5. Current Symptoms
Table 6. Treatments
Show moreShow less
Additional material (1)
Introduction and objectives

Coronary artery disease is associated with high morbidity and mortality. The objective of the CLARIFY registry is to study the treatment of outpatients with coronary artery disease in the setting of daily clinical practice.


The CLARIFY registry is a prospective registry conducted in 41 countries that included outpatients with stable coronary artery disease attending primary care or specialist units between October 2009 and June 2010. The present study describes the baseline characteristics of the Spanish cohort compared with the western European cohorts included in the registry.


A total of 33 248 patients were included: 14 726 in western Europe and 2257 in Spain (selected by 192 cardiologists). The majority of the participants in Spain were men (81%) with a mean age of 65 years. There was a higher frequency of diabetes (34% vs 25%; P<.0001), coronary artery disease family history (19% vs 31%; P<.0001), myocardial infarction (64% vs 60%; P<.0001), and stroke (5% vs 3%; P=.0007) in the Spanish cohort than in the western European cohorts. The most common treatments in the Spanish sample were lipid-lowering drugs (96%), acetylsalicylic acid (89%), and beta-blockers (74%).


Patients in the Spanish cohort are similar to those in the western European cohorts and seem to be representative of the Spanish population with coronary artery disease. Therefore, they form a suitable basis for the study of prognostic factors at 5-year follow-up.

Coronary artery disease
Risk factors
Introducción y objetivos

La enfermedad arterial coronaria se asocia con elevada morbimortalidad. El objetivo de este registro es conocer la realidad de la práctica clínica diaria de pacientes ambulatorios con enfermedad arterial coronaria.


Registro prospectivo realizado en 41 países en el que se incluyó a pacientes ambulatorios con enfermedad arterial coronaria estable que acudieron a consultas de atención primaria o especializada entre octubre de 2009 y junio de 2010. En este trabajo se describen las características de la visita basal de la cohorte española y su comparación con los demás países de Europa occidental participantes en el registro.


Se incluyó a 33.248 pacientes, 14.726 en Europa occidental y 2.257 en España (por 192 especialistas en Cardiología). En España, la media de edad fue 65 años, la mayoría varones (81%). En la cohorte española, respecto al resto de Europa occidental, se observó mayor frecuencia de diabetes mellitus (el 34 frente al 25%; p < 0,0001), infarto de miocardio (el 64 frente al 60%; p < 0,0001) e ictus (el 5 frente al 3%; p = 0,0007) y menor frecuencia de antecedentes familiares de enfermedad arterial coronaria (el 19 frente al 31%; p < 0,0001). Los tratamientos más comunes en la muestra española fueron los hipolipemiantes (96%), el ácido acetilsalicílico (89%) y los bloqueadores beta (74%).


Los pacientes de la cohorte española son similares a los de los demás países europeos participantes en el registro y parecen ser representativos de la población española con enfermedad arterial coronaria. Por lo tanto, constituyen una buena base para el estudio de los factores pronósticos que se pretende realizar a los 5 años de seguimiento.


Palabras clave:
Enfermedad arterial coronaria
Factores de riesgo
Full Text

Coronary artery disease (CAD) remains the leading cause of death in Europe.1 However, data released in 2008 show a recent fall in CAD mortality in most European countries, due to advances in prevention strategies and more effective treatments, whereas it has risen in some central and eastern European countries.1 Although these advances have improved CAD outcomes, the number of CAD patients has increased, changing the clinical practice setting and leading to the high economic burden of €192 billion per year in the European Union.1

The high prevalence, morbidity and mortality, and economic burden of CAD have led to changes in the European guidelines on cardiovascular disease prevention.2 These changes include new sections on risk factors, such as heart rate (HR). The importance of HR in the outcome of stable CAD patients has been supported by extensive evidence.3

Information on patients seen in daily clinical practice is needed to determine to what extent the recommendations are being applied and to what degree disease outcomes are improving. Patient data from clinical trials are useful for evaluating treatment, but do not represent clinical practice due to the stringent patient selection process and because patient follow-up and treatment is guided by the trial protocol. Patient registries are the ideal source of information on CAD patients. Although several CAD patient registries have recently been developed, they are limited by being restricted to a particular geographical area4 or by only addressing certain CAD conditions, especially stable angina5 or acute coronary syndrome.6,7

The CLARIFY8,9 registry was developed with the main aim of obtaining worldwide data on the treatment of all CAD outpatients in the setting of daily clinical practice and of identifying the determinants, including HR, of long-term outcomes in this population. Even though HR has been associated with increased cardiovascular risk10 it is not yet a routine component of cardiovascular assessment; furthermore, its prognostic value and to what extent it is applied in clinical practice remains unknown. This paper describes and compares the demographic and clinical characteristics of the Spanish cohort with other western European cohorts.


CLARIFY is an international prospective registry, launched in 41 countries worldwide. Its main objective is to describe the demographic and clinical characteristics of stable CAD outpatients seen in daily clinical practice by the medical specialists (cardiologists, internists, and primary care physicians) in charge of managing these patients in each participating country. A secondary objective is to develop a risk prediction model by identifying long-term prognostic factors, including resting HR. The CLARIFY study is being conducted in accordance with the principles embodied in the Declaration of Helsinki. The present study was reviewed and approved by the Clinical Research Ethics Committee of the Hospital Clínico San Carlos in Madrid.

The CLARIFY study population consists of stable CAD outpatients attending primary care centers or specialist units (cardiology and internal medicine) worldwide. In each country, the national coordinators selected the participating centers according to the distribution of coronary patients and the health care organizational structure, such that the sample was representative of the epidemiological patterns in each country. Each selected physician included the first 10 consecutive patients attending his or her center who met the eligibility criteria. The national coordinators of the CLARIFY registry in Spain decided that only cardiologists who were based in hospitals or outpatient centers could participate because these specialists are responsible for making decisions about stable CAD patients. The list of researchers is shown in the supplementary material.

The registry includes stable CAD outpatients with at least 1 of the following conditions: documented myocardial infarction that occurred more than 3 months earlier; at least 1 coronary stenosis blocking>50% of the artery on angiography; chest pain with myocardial ischemia confirmed by stress electrocardiogram, stress echocardiography, or myocardial imaging; coronary artery bypass graft or percutaneous coronary intervention conducted more than 3 months before inclusion. Patients were excluded if they had been hospitalized for cardiovascular disease in the last 3 months, were scheduled for revascularization, or their condition hindered their participation in the study and the 5-year follow-up period.

Patients were recruited between October 2009 and June 2010 worldwide and from April to June 2010 in Spain. All patients will be followed up for 5 years with annual visits. Data collection is by electronic forms translated into the local language. At baseline, patients were evaluated for demographic information, risk factors, lifestyle, medical history, physical examination, current symptoms, data from the most recent tests, and current chronic medical treatments. At the annual visits, this information is updated and data are collected on the patient's clinical course and cardiovascular mortality and morbidity. This is an observational study and thus all the information is collected during daily clinical practice in each center, as documented in the patients’ medical history.

Based on data from previous studies,5 the total size of the sample of the registry was determined by estimating cardiovascular mortality and mortality or cardiovascular events to be 2% and 4.5% per year, respectively. At least 31 000 participants are expected to be selected with an estimated 5% loss to follow-up per year. Thus, the expected number of cardiovascular deaths will be approximately 2300. On the basis of the analysis of HR as a categorical variable (population divided into HR quartiles), we used a conservative approach that compared the highest HR quartile to the other quartiles to establish the risk of cardiovascular mortality. This comparison resulted in a minimum statistical power of 80% to identify a 20% increase in risk for the group with the highest HR. If HR is considered a continuous variable, a power of 90% to detect an instantaneous hazard ratio of 1.06 for each 10 bpm increase in HR would be obtained at a significance level of 5%. In general, each participating country had to recruit a mean of 25 patients (range, 12.5-50) per million population to obtain a representative sample.

The post hoc analysis presented in this article describes the baseline characteristics of the sample in Spain and other western European countries (Germany, Austria, Belgium, Denmark, France, Greece, Ireland, Italy, the Netherlands, Portugal, Switzerland, the United Kingdom) participating in the CLARIFY registry. Continuous variables are expressed as mean (standard deviation) or median [interquartile range] according to the data distribution. Categorical variables are expressed as absolute frequencies and percentages. Continuous variables (Spanish subcohort vs western European subcohorts) were compared using simple analysis of variance (ANOVA) or the Kruskal-Wallis test according to the data distribution. Categorical variables were compared using the chi-square test. In all cases, the results were considered significant when P<.05.


The CLARIFY registry included 33 248 participants from 41 countries, of whom 14 726 were from the western European countries included in the present analysis. A total of 192 cardiologists recruited the 2257 participants from Spain. The demographic characteristics of the patients from Spain and the rest of the sample are summarized in Table 1. The majority of the participants were men (81% in Spain and 79% in the rest of the sample) and mean age was 65 years in the Spanish sample and 66 years in the remaining sample.

Table 1.

Sociodemographic Characteristics

  Spain (n=2257)  Other countries (n=12 469)  P 
Age, mean (SD), y  65.3 (10.8)  66.3 (10.0)  <.0001 
Men  1817 (81)  9889 (79.4)  .0756 
Caucasian  2133 (94.5)  9010 (72.3) 
Employment      <.0001 
Full-time  546 (24.3)  2600 (20.9)   
Half-time  71 (3.2)  661 (5.3)   
Disabled  155 (6.9)  322 (2.6)   
Unemployed  61 (2.7)  322 (2.6)   
Retired  1329 (59.1)  8305 (66.7)   
Other  86 (3.8)  249 (2)   
Education      <.0001 
Primary (or less)  1180 (52.5)  3654 (29.3)   
Secondary  739 (32.9)  6186 (49.7)   
University  329 (14.6)  2619 (21.0)   

SD, standard deviation.

* Not calculated.

Unless otherwise indicated, the data are expressed as No. (%).

Risk factors and lifestyle habits are shown in Table 2. The percentage of current smokers was lower in Spain than in the other western European countries, and the percentage of exsmokers was higher in Spain (Table 2). In the Spanish sample, 78% of patients had dyslipidemia, 68% had hypertension, 34% had diabetes mellitus (DM), and 13% had peripheral artery disease. The greatest differences between Spain and the other western European countries were in the prevalence of DM (34% vs 25%, P<.0001) and in having a family history of premature CAD (19% vs 31%, P<.0001). Myocardial infarction (64% vs 60%, P<.0001) and stroke (5% vs 3%, P=.0007) were more common in Spain than in the rest of the sample, whereas carotid artery disease was less common in Spain (5% vs 9%, P<.0001) (Table 3). Tables 4 and 5 show the clinical profile and baseline symptoms of the patients.

Table 2.

Risk Factors and Lifestyle Habits

  Spain (n=2257)  Other countries (n=12 469)  P 
Family history of premature CAD  429 (19.1)  3805 (30.5)  <.0001 
Treated hypertension  1518 (67.5)  8460 (67.9)  .7253 
Diabetes mellitus  753 (33.5)  3138 (25.2)  <.0001 
Dyslipidemia  1743 (77.5)  9520 (76.4)  .2464 
Peripheral artery disease  297 (13.2)  1537 (12.3)  .2482 
Smoking      <.0001 
Smoker  211 (9.4)  1467 (11.8)   
Exsmoker  1323 (58.9)  6105 (49.0)   
Nonsmoker  714 (31.8)  4888 (39.2)   
Alcohol consumption (drinks/wk)      <.0001 
980 (43.6)  3974 (31.1)   
>0 and<20  1129 (50.2)  7868 (63.2)   
>20  139 (6.2)  616 (5.0)   
Stimulant drinks      <.0001 
Cafe  1061 (47.2)  7693 (61.8)   
Tea  53 (2.4)  2576 (20.7)   
None  1134 (50.4)  2188 (17.6)   
Weekly physical activity      <.0001 
None  338 (15.0)  2209 (17.8)   
Light physical activity most weeks  1193 (53.1)  5902 (47.4)   
Vigorous physical activity for at least 20 min, 1-2 times/wk  349 (15.5)  2350 (18.9)   
Vigorous physical activity ≥20 min ≥3 times/wk  368 (16.4)  1994 (16.1)   

CAD, coronary artery disease.

Data are expressed as No. (%).

Table 3.

Medical History

  Spain (n=2257)  Other countries (n=12 469)  P 
Confirmed CAD       
Myocardial infarction  1430 (63.6)  6988 (59.1)  <.0001 
PCI  1388 (61.7)  7692 (61.7)  .9962 
Revascularization surgery  433 (19.3)  3391 (27.2)  <.0001 
Abdominal aortic aneurysm  54 (2.4)  306 (2.5)  .8809 
Carotid artery disease  121(5.4)  1087 (8.7)  <.0001 
Implantable cardioverter-defibrillator  48 (2.1)  228 (1.8)  .3263 
Pacemaker  66 (3.0)  393 (3.2)  .5836 
Stroke  101 (4.5)  386 (3.1)  .0007 
Transient ischemic attack  75 (3.3)  413 (3.3)  .956 
Hospitalized for CHF  116 (5.2)  459 (3.7)  .0009 
Atrial fibrillation/flutter  203 (9.0)  1047 (8.4)  .3268 
Asthma/COPD  235 (10.5)  1166 (9.4)  .0904 

CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; PCI, percutaneous coronary intervention.

Data are expressed as No. (%).

Table 4.

Baseline Clinical Profile

  Spain (n=2257)  Other countries (n=12 469)  P 
BMI, kg/m2  27.8 [25.7-30.5]  27.5 [25.1-30.4]  <.0001 
Waist circumference, cm  99 [91-106]  99 [90-107]  .9446 
SBP, mean (SD), mmHg  131 (16)  131 (16)  .3225 
DBP, mean (SD), mmHg  76 (10)  77 (9)  <.0001 
HR by pulse palpation, mean (SD), bpm  66 (11)  66 (11)  .0018 
HR on ECG, mean (SD), bpm  65 (11)  65 (11)  .1046 
Sinus rhythm  1942 (93)  8881(94)  .4721 
Atrial fibrillation/flutter  95 (5)  387 (4)   
Paced rhythm  48 (2)  194 (2)   
LBBB  154 (7)  501(5)  .0002 

BMI, body mass index; DBP, diastolic blood pressure; ECG, electrocardiogram; HR, heart rate; LBBB, left bundle branch block; SBP, systolic blood pressure; SD, standard deviation.

Unless otherwise indicated, the data are expressed as No. (%) or median [interquartile range].

Table 5.

Current Symptoms

  Spain (n=2257)  Other countries (n=12 469)  P 
Angina  489 (21.8)  1565 (12.6)  <.0001 
CCS I  161 (7.2)  561 (4.5)  <.0001 
CCS II  283 (12.6)  760 (6.1)   
CCS III  43 (1.91)  211 (1.7)   
CCS IV  2 (0.1)  32 (0.3)   
CHF symptoms       
No symptoms  2084 (92.8)  11 581 (93.0)  .8992 
With NYHA II symptoms  137 (6.1)  729 (5.9)   
With NYHA III symptoms  26 (1.2)  147 (1.2)   

CCS, Canadian Cardiovascular Society class; CHF, congestive heart failure; NYHA, New York Heart Association functional class.

Data are expressed as No. (%).

Table 6 shows the treatment the patients were receiving at the time of the baseline visit. The most common treatments in the Spanish sample were lipid-lowering drugs (96%), aspirin (89%), and beta-blockers (74%). The greatest difference between Spain and the other western European countries was in the higher frequency of specific treatments such as ivabradine, antidiabetic agents, long-acting nitrates, and proton pump inhibitors in the Spanish cohort.

Table 6.


  Spain (n=2257)  Other countries (n=12 469)  P 
Cardiovascular treatments       
Antiplatelet agents       
ASA  1994 (88.74)  10 477 (84.13)  <.0001 
Thienopyridine  656 (29.27)  3184 (25.59)  .0003 
Other antiplatelet agents  202 (8.99)  939 (7.55)  .0187 
Anticoagulants  214 (9.52)  1191 (9.56)  .9516 
Beta-blockers  1659 (73.83)  9005 (72.31)  .1373 
Ivabradine  443 (19.72)  1440 (11.56)  <.0001 
Calcium channel blockers  668 (29.73)  3065 (24.62)  <.0001 
ACEI and/or ARB  1639 (72.94)  9419 (75.64)  .0065 
Lipid-lowering drugs  2148 (95.59)  11 535 (92.63)  <.0001 
Long-acting nitrates  710 (31.6)  1989 (15.97)  <.0001 
Other antiangina drugs  116 (5.17)  869 (6.98)  .0016 
Diuretics  651 (28.98)  3813 (30.62)  .12 
Other antihypertensive drugs  126 (5.61)  897 (7.2)  .0064 
Digoxin and derivatives  61 (2.71)  244 (1.96)  .0208 
Amiodarone/dronedarone  63 (2.80)  373 (3)  .6221 
Other antiarrhythmic drugs  15 (0.67)  137 (1.1)  .0617 
Other treatments       
NSAIDs  104 (4.64)  642 (5.16)  .3025 
Antidiabetic agents  682 (30.35)  2667 (21.42)  <.0001 
Proton pump inhibitors  1279 (56.95)  4032 (32.38)  <.0001 
THRT  69 (3.07)  772 (6.2)  <.0001 
HRT in postmenopausal women  3 (0.13)  54 (0.43)  .04 
Treatment for erectile dysfunction  53 (2.36)  277 (2.22)  .6936 

ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor antagonists; ASA, acetylsalicylic acid; HRT, hormone replacement therapy; NSAIDs, nonsteroid anti-inflammatory agents; THRT, thyroid hormone replacement therapy.

Data are expressed as No. (%).


The results of this study show that the sociodemographic and clinical characteristics of the stable CAD patients in the Spanish cohort of the CLARIFY registry are similar to those of patients in the other participating western European countries. These characteristics appear to be representative of the Spanish population with CAD, since they are generally similar to those reported by other studies that also included patients with CAD in both local4 and international settings.11,12

More than half of the participants in the Spanish sample were men with a mean age of approximately 65 years, which is similar to the mean age previously observed in this population.4,11,13 Some significant differences were found between the Spanish cohort and the other cohorts, although in principle these differences were not expected. The observed difference in some demographic characteristics, such as age, may have been the result of minor differences of little importance but which became statistically significant due to the large sample size. The observed differences in educational level may have been partly due to differences in the way education systems are classified in each country. There were also unexpected differences in having a family history of CAD or DM. These differences may have been due to under-reporting by the cardiologists, rather than to a real difference between groups.

Tobacco consumption was low, and the percentage of smokers (9%) was similar to that reported in other Spanish registries on coronary heart disease.4,13 The percentage of smokers was also slightly lower than in the other western European countries, a finding that has also been reported in other international registries that included Spanish patients with coronary heart disease.11,13 Comparative studies conducted in Europe in CAD patients show a decrease in tobacco consumption in Spain over the last 10 years (18% in Spain vs 21% in Europe).14 This trend reflects a change in lifestyle among CAD patients in Europe; the need to decrease tobacco consumption has been demonstrated and remains a fundamental aspect for the secondary prevention of CAD.2

The pattern of other risk factors is consistent with that previously observed in this population.4,11,13,14 Thus, the prevalence of DM in the Spanish cohort was similar to that observed in other registries11,13,14 and somewhat lower than that reported in patients with high cardiovascular risk.15,16 The rate of hypertension was also similar to that reported in other studies11,13 and lower than that observed in patients with acute CAD.16

Although the differences in clinical profile between the Spanish cohort and the western European cohorts in parameters such as body mass index, diastolic blood pressure and HR were statistically significant (P<.05) (Table 4), the absolute value of these differences was of no clinical relevance. The mean blood pressure in all the CLARIFY cohorts was within the range recommended by the clinical practice guidelines2 and was slightly lower than that recently observed in CAD patients in Europe.12 However, the average resting HR (65 bpm) in all the cohorts exceeded the recommended target rate (55-60 bpm).17 Recently published data from the entire CLARIFY registry show that an HR>60 bpm was associated with a higher prevalence and greater severity of angina.9 These data indicate the need for improved treatment to reduce HR in patients with stable angina to the recommended target rate of 60 bpm.17

The most pronounced differences between the Spanish and European cohorts were related to specific treatments. Although demographic and clinical characteristics did not generally differ between cohorts, the differences observed in treatment could indicate different clinical practices in each country, thus underlining the need for an international registry similar to that presented here. Follow-up data from the registry are needed to understand the prognostic implications of these differences. To date, data from the baseline visit only show that there are specific differences in treatments between the Spanish and western European cohorts. These differences mainly involve the use of cardiovascular drugs such as ivabradine and long-acting nitrates, which were more frequently used in the Spanish sample (20% and 32%, respectively) than in the other European countries (12% and 16%, respectively). However, the observed difference in the use of antidiabetic agents (30% in the Spanish cohort and 21% in the other cohorts) could be explained by the higher prevalence of DM recorded in Spain (34% in Spain and 25% in other western European countries). Furthermore, the increased use of proton pump inhibitors in the Spanish cohort is striking compared with the other cohorts and with other treatments. Although the abuse of these drugs in Spain is well known,18,19 the marked difference between Spain and the other countries cannot be explained by differences in age or in the use of medications that increase the risk of bleeding, since both factors are similar in both groups. In the absence of additional data on comorbidities that may be associated with this increase, it can only be speculated that the use of these drugs in Spanish clinical practice must strongly differ from their use in the other western European countries in the registry.

Overall, the pattern of use of cardiovascular drugs reported in the CLARIFY registry is similar to that previously reported for the Spanish population with CAD, with the exception of specific treatments such as beta-blockers and lipid-lowering drugs, whose use is slightly higher than that reported in similar registries.4,11,20 The number of prescriptions for beta-blockers is even higher than that previously observed in patients hospitalized with acute myocardial infarction.21 The clinical practice guidelines recommend beta-blockers in these patients and even in patients with type II diabetes. The widespread use of antiplatelet agents was similar to that observed in the total sample and to that published by other studies,4,12 but was slightly higher than in other registries.20 The level of use is consistent with the clinical guidelines, which recommend antiplatelet therapy in all patients with CAD unless contraindicated.2 The cross-sectional design of the present study does not allow assessment of the degree of nonadherence with clinical practice guidelines in drug prescription and its possible causes; however, this information can be analyzed during follow-up of the registry, which, unlike previous registries,22 has the advantage that it will allow longitudinal and prospective data collection.

Furthermore, this prospective registry is ongoing and we expect to be able to construct a prediction model that includes factors such as DM, dyslipidemia, obesity23 and HR,3 with a demonstrated important prognostic role in the mortality rates of these patients. Finally, the CLARIFY registry will identify and provide patient cohorts that could be of interest to future clinical studies on improving the management of CAD. It would also be of interest to assess whether there are differences between specific subgroups, since there appear to be differences, for example, between men and women in the control of risk factors after an acute coronary episode24 despite their receiving similar treatment.24,25

Strengths and Limitations

Some limitations should be considered when interpreting the results of this study, such as the use of convenience sampling rather than randomized sampling to select the centers and patients. The use of this method raises the issue of whether the sample is representative of the population under study. However, several aspects can be cited in favor of its representativeness, such as the large number of patients enrolled in the study and, in particular, the similarity of its results with those of other studies in this patient population. Despite these limitations, the registry has several strengths, including the large number of participating countries, making the results more generalizable. The CLARIFY registry is not restricted to a particular geographical area and provides information on daily clinical practice in stable CAD patients.


The baseline data provided by the CLARIFY registry indicate that the stable CAD patients in the Spanish sample appear to be representative of the Spanish population with CAD and are similar to stable CAD patients in other western European countries. The results of the 5-year follow-up will provide information on how these patients are managed in clinical practice and the degree of adherence to the recommendations of the clinical practice guidelines, leading to improvements in the treatment of this patient population.


Laboratorios Servier S.L.


None declared.


In Spain, the CLARIFY registry was organized and managed by the Spanish Society of Cardiology via its Research Agency, which was funded by Laboratorios Servier S.L. Data analysis was conducted by the Robertson Centre for Biostatistics at Glasgow University, UK. We would like to thank Teresa Hernando (Cociente S.L.) for her assistance in writing this article.

European cardiovascular disease statistics 2008. European Heart Network; 2008 [accessed 11 Oct 2011]. Available at:
J. Perk, G. De Backer, H. Gohlke, I. Graham, Z. Reiner, M. Verschuren, et al.
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts).
Eur Heart J, 33 (2012), pp. 1635-1701
A. Diaz, M.G. Bourassa, M.C. Guertin, J.C. Tardif.
Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease.
Eur Heart J, 26 (2005), pp. 967-974
A. Cordero, V. Bertomeu-Martinez, P. Mazon, J. Quiles, J. Aznar, H. Bueno.
Differences in medical treatment of chronic coronary heart disease patients according to medical specialities.
Cardiovasc Ther, 27 (2009), pp. 173-180
C.A. Daly, F. Clemens, J.L. Sendon, L. Tavazzi, E. Boersma, N. Danchin, et al.
The clinical characteristics and investigations planned in patients with stable angina presenting to cardiologists in Europe: from the Euro Heart Survey of Stable Angina.
Eur Heart J, 26 (2005), pp. 996-1010
Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: a multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J. 2001;141:190-9.
H. Bueno, A. Bardají, A. Fernández-Ortiz, J. Marrugat, H. Martí, M. Heras.
Manejo del síndrome coronario agudo sin elevación del segmento ST en España. Estudio DESCARTES (Descripción del Estado de los Síndromes Coronarios Agudos en un Registro Temporal Español).
Rev Esp Cardiol, 58 (2005), pp. 244-252
CLARIFY registry launched in South Africa. Cardiovasc J Afr. 2010;21:170.
P.G. Steg, R. Ferrari, I. Ford, N. Greenlaw, J.C. Tardif, M. Tendera, et al.
Heart rate and use of beta-blockers in stable outpatients with coronary artery disease.
K. Fox, I. Ford, P.G. Steg, M. Tendera, M. Robertson, R. Ferrari.
Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial.
E. Esmatjes, A.J. Blanco.
[The REACH registry: baseline and 1-year results].
Med Clin (Barc), 132 (2009), pp. 5-9
K. Kotseva, D. Wood, G. De Backer, D. De Bacquer, K. Pyorala, U. Keil.
EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries.
Eur J Cardiovasc Prev Rehabil, 16 (2009), pp. 121-137
C. Suarez.
Baseline characteristics of patients with cerebrovascular disease in the REACH registry: the Spanish contribution.
Cerebrovasc Dis, 24 (2007), pp. 89-95
Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J. 2001;22:554-72.
A. de la Peña Fernández, C. Suárez Fernández, I. Cuende Melero, M. Muñoz Rodríguez, J. Garre Canovas, M. Camafort Babkowski, et al.
[Integral control of risk factors in patients of high and very high cardiovascular risk in Spain, CIFARC project].
Med Clin (Barc), 124 (2005), pp. 44-49
A. Cabades, L. Lopez-Bescos, F. Aros, A. Loma-Osorio, X. Bosch, P. Pabon, et al.
Variabilidad en el manejo y pronóstico a corto y medio plazo del infarto de miocardio en España: el estudio PRIAMHO.
Rev Esp Cardiol, 52 (1999), pp. 767-775
R.J. Gibbons, J. Abrams, K. Chatterjee, J. Daley, P.C. Deedwania, J.S. Douglas, et al.
ACC/AHA 2002 guideline update for the management of patients with chronic stable angina—summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina).
J Am Coll Cardiol, 41 (2003), pp. 159-168
C. deBurgos Lunar, S. Novo del Castillo, E. Llorente Diaz, M.A. Salinero Fort.
[Study of prescription-indication of proton pump inhibitors].
Rev Clin Esp, 206 (2006), pp. 266-270
E. Ramirez, S.H. Lei, A.M. Borobia, E. Pinana, S. Fudio, R. Munoz, et al.
Overuse of PPIs in patients at admission, during treatment, and at discharge in a tertiary Spanish hospital.
Curr Clin Pharmacol, 5 (2010), pp. 288-297
J.F. Gomez Cerezo.
[Use of drugs in the REACH registry: from guidelines to clinical practice].
Med Clin (Barc), 132 (2009), pp. 44-46
F. Aros, J. Cunat, A. Loma-Osorio, E. Torrado, X. Bosch, J.J. Rodriguez, et al.
Tratamiento del infarto agudo de miocardio en España en el año 2000. El estudio PRIAMHO II.
Rev Esp Cardiol, 56 (2003), pp. 1165-1173
L. Roa, M. Monreal, J.A. Carmona, E. Aguilar, R. Coll, C. Suarez.
[Treatment inertia in secondary prevention of cardiovascular disease. FRENA registry].
Med Clin (Barc), 134 (2010), pp. 57-63
C. Prugger, U. Keil, J. Wellmann, D. De Bacquer, G. De Backer, G.B. Ambrosio, et al.
Blood pressure control and knowledge of target blood pressure in coronary patients across Europe: results from the EUROASPIRE III survey.
J Hypertens, 29 (2011), pp. 1641-1648
J. Dallongevillle, D. De Bacquer, J. Heidrich, G. De Backer, C. Prugger, K. Kotseva, et al.
Gender differences in the implementation of cardiovascular prevention measures after an acute coronary event.
Heart, 96 (2010), pp. 1744-1749
A. Reina, M. Colmenero, E. Aguayo de Hoyos, F. Aros, H. Marti, R. Claramonte, et al.
Gender differences in management and outcome of patients with acute myocardial infarction.
Int J Cardiol, 116 (2007), pp. 389-395
Copyright © 2013. Sociedad Española de Cardiología
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

View newsletter history
Article options
Supplemental materials
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?